RE:RE:RE:RE:RE:RE:Valstar Clinical Trial: 98% of Patients Were White!!!txb...I am starting to get around to what you are trying to accomplish.
I think the focus should be twofold. First, contacting urologists is probably a worthwhile effort. Their opinion matters the most. A concise letter as to what happened at the AdComm, includiing the posible ramifications for MCNA as a result, coupled with a synopsis of the data and trial limitations could sway enough Urologists to get behind a petition or sign a form letter. Contact information should be readily available through AUA.
I am not verse as to how the FDA would think of this type of influence tactic, maybe someone who has managements ear could explore.
I hope this is not over, obviously for my accounts, but also, because this drug seems to work, and the only real way to tell how well, is to release it into the urologists hands as a tool of option when they se fit.
I will PM you since we should help out with any out of pocket expenses you incur.
GLTA